Maverix Biomics Inc. has signed a strategic cooperation agreement with STM publisher Elsevier to streamline the interpretation of raw next-generation sequencing (NGS) data to reveal new insights and to assist with critical decision making. The announcement was made at the 23rd International Molecular Medicine Tri-Conference (Tricon) in San Francisco CA.
The Maverix Analytic Platform will complement Pathway Studio's sample-to-insight workflow and incorporation of biological data from Elsevier's biology journals by providing easy, push-button data analysis, which is now integrated with Elsevier's Pathway Studio research solution for biologists. Financial terms were not disclosed.
The combination of the Maverix Analytic Platform and Elsevier's Pathway Studio is an integrated solution that starts with raw NGS data and quickly produces genome alignment, quality metrics, variant and expression analysis, and the ability to analyse and visualise disease mechanisms derived from published scientific data.
Pathway Studio is an integrated data mining and visualisation software with a high-quality, comprehensive knowledgebase produced by applying Elsevier's proprietary text-mining technology to a large corpus of biological literature. Pathway Studio allows organisations and researchers to rapidly connect relevant biological facts and relationships, integrate and interpret experimental data, and visualise the results.
